Active lawsuitDangerous drugsMDL No. 3180
Dupixent lymphoma lawsuits
Dupixent (dupilumab) is a prescription biologic medicine commonly prescribed for eczema (atopic dermatitis) and other conditions. People who used Dupixent and were later diagnosed with cutaneous T-cell lymphoma (CTCL), a cancer of white blood cells that shows up in the skin, have filed lawsuits alleging the medicine caused or accelerated their cancer and that the makers did not adequately warn. In June 2026, these federal cases were brought together before one judge. Our legal team reviews these cases, and you can ask for a free case evaluation.
the pharmacy label has the dates
This page summarizes what pending lawsuits allege, based on court records and official sources. Allegations in a lawsuit are not findings by a court. It's general information, not legal advice about your situation. Last reviewed October 12, 2026.
On this page
Safety note: Don't stop or change a prescribed medicine without talking to your doctor.
At a glance
Dupixent (Dupilumab) Lymphoma Lawsuits
- Litigation
- In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180
- Court
- U.S. District Court for the District of New Jersey
- Judge
- Judge Zahid N. Quraishi
- Centralized
- June 4, 2026
- Companies named
- Regeneron Pharmaceuticals, Inc.; Sanofi-Aventis U.S. LLC; Genzyme Corporation
What the lawsuits allege
- CTCL. Plaintiffs allege that Dupixent caused them to develop cutaneous T-cell lymphoma, or accelerated a CTCL they already had.
- Knowledge and warnings. The lawsuits raise whether the scientific literature shows a causal link between Dupixent and CTCL, when the makers should have learned about it, and whether they provided adequate warnings about Dupixent's risks.
- Family claims. Some plaintiffs are the spouses or survivors of Dupixent users who were diagnosed with CTCL.
The MDL covers CTCL claims. The Panel left open whether cases involving other T-cell lymphomas belong in it, and the MDL does not include B-cell lymphoma or Hodgkin's lymphoma claims. An MDL means many people have filed similar lawsuits. It does not mean any court has decided that Dupixent caused anyone's cancer.
Who may be eligible
You may be eligible for a free case evaluation if you used Dupixent (dupilumab) and were later diagnosed with cutaneous T-cell lymphoma (CTCL).
If your spouse or a family member who died used Dupixent and was diagnosed with CTCL, you can also ask for a free case evaluation.
Our attorneys look at
- When you started and stopped Dupixent, and what it was prescribed for
- When and how the CTCL was diagnosed, including the biopsy and pathology results
- Whether an earlier skin diagnosis was later revised
What to gather for your free evaluation
You don't need everything on this list to ask for an evaluation. Gather what you can.
- Pharmacy or specialty-pharmacy records showing Dupixent and the dates you used it
- The name of the doctor who prescribed it
- Dermatology records from before and after you started Dupixent
- Skin biopsy and pathology reports, and the date of your CTCL diagnosis
- Records from your oncologist and of any treatment
- A short timeline of your symptoms and diagnoses
Where the litigation stands
As of October 2026
- LitigationMDL No. 3180
- CourtU.S. District Court for the District of New Jersey
- JudgeJudge Zahid N. Quraishi
- CreatedJune 4, 2026
As of October 2026, lawsuits allege that Dupixent caused cutaneous T-cell lymphoma or accelerated a preexisting CTCL, and that the defendants did not provide adequate warnings. The Judicial Panel on Multidistrict Litigation created the MDL on June 4, 2026, and assigned it to Judge Zahid N. Quraishi in the District of New Jersey. The litigation is at an early pretrial stage.
Reporting a side effect
Side effects of a prescription medicine can be reported to the FDA through MedWatch. Don't stop or change a prescribed medicine without talking to your doctor.
Status checked October 12, 2026. This MDL is listed as pending on the JPML report of pending MDLs dated October 1, 2026 (opens in a new tab). Court dockets change; each page shows the date it was last checked.
Questions
I still use Dupixent. Should I stop?
Not without talking to your doctor. Stopping or changing a prescribed medicine on your own can cause problems. A case evaluation doesn't require you to change your treatment.
My diagnosis is a different kind of lymphoma. Can I still ask?
You can ask. The MDL currently covers CTCL. The Panel left open whether other T-cell lymphomas belong in it, and it does not include B-cell or Hodgkin's lymphoma. Our attorneys will review your specific diagnosis.
Is this a class action?
No. In an MDL, each person keeps an individual lawsuit. The cases are grouped before one federal judge for pretrial work.
Is there a deadline?
Yes. Each state sets its own filing deadline, called a statute of limitations, and an MDL does not pause it. The deadline that applies depends on your state and when you learned of your diagnosis, so it's best to ask early.
Official sources
Each link opens the original record in a new tab.
- Judicial Panel on Multidistrict LitigationJPML Transfer Order, MDL No. 3180 (filed June 4, 2026)jpml.uscourts.gov (opens in a new tab)
- Judicial Panel on Multidistrict LitigationJPML: Pending MDL Dockets by MDL Type, report date October 1, 2026jpml.uscourts.gov (opens in a new tab)
- U.S. Food and Drug AdministrationFDA MedWatch: report a problem with a medicinefda.gov (opens in a new tab)
Used Dupixent and were diagnosed with CTCL?
Tell us what happened in a few sentences. Our legal team reviews every request, and we will contact you about your free case evaluation.
a few sentences is enough
A free case evaluation does not create an attorney-client relationship, does not file a claim and does not pause any deadline. We represent a client only after we both sign a written agreement.
a few sentences is enough